
RCUS
Arcus Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.240
Open
9.880
VWAP
10.11
Vol
713.70K
Mkt Cap
1.08B
Low
9.610
Amount
7.21M
EV/EBITDA(TTM)
--
Total Shares
90.95M
EV
134.20M
EV/OCF(TTM)
--
P/S(TTM)
6.76
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
34.78M
-3.4%
-1.210
+17.51%
32.48M
-32.33%
-1.182
+18.23%
32.86M
-15.75%
-1.165
+14.25%
Estimates Revision
The market is revising Downward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by -16.8% over the past three months. During the same period, the stock price has changed by 24.00%.
Revenue Estimates for FY2025
Revise Downward

-16.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+19.48%
In Past 3 Month
Stock Price
Go Up

+24.00%
In Past 3 Month
9 Analyst Rating

147.21% Upside
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 25.29 USD with a low forecast of 12.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy

147.21% Upside
Current: 10.230

Low
12.00
Averages
25.29
High
46.00

147.21% Upside
Current: 10.230

Low
12.00
Averages
25.29
High
46.00
Barclays
Peter Lawson
Buy
Maintains
$29 → $14
2025-04-23
Reason
Barclays
Peter Lawson
Price Target
$29 → $14
2025-04-23
Maintains
Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
to
Strong Buy
Upgrades
$24
2025-02-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$24
2025-02-26
Upgrades
Hold
to
Strong Buy
Reason
B of A Securities
Jason Zemansky
Hold
Maintains
$22 → $17
2025-02-19
Reason
B of A Securities
Jason Zemansky
Price Target
$22 → $17
2025-02-19
Maintains
Hold
Reason
Morgan Stanley
Terence Flynn
Buy
Maintains
$36 → $25
2025-02-18
Reason
Morgan Stanley
Terence Flynn
Price Target
$36 → $25
2025-02-18
Maintains
Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Maintains
$20 → $18
2025-02-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$20 → $18
2025-02-18
Maintains
Hold
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
$20
2024-11-06
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$20
2024-11-06
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -2.25, compared to its 5-year average forward P/E of -6.27. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-6.27
Current PE
-2.25
Overvalued PE
-1.62
Undervalued PE
-10.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-4.29
Current EV/EBITDA
-0.26
Overvalued EV/EBITDA
0.57
Undervalued EV/EBITDA
-9.16
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
15.74
Current PS
6.95
Overvalued PS
25.63
Undervalued PS
5.85
Financials
Annual
Quarterly
FY2025Q1
YoY :
-80.69%
28.00M
Total Revenue
FY2025Q1
YoY :
-3150.00%
-122.00M
Operating Profit
FY2025Q1
YoY :
+2700.00%
-112.00M
Net Income after Tax
FY2025Q1
YoY :
+2180.00%
-1.14
EPS - Diluted
FY2025Q1
YoY :
+2116.67%
-133.00M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+14392.75%
-400.00
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
20.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
3
15.4M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 186.42% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
87.5K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
6.9M
Volume
Months
6-9
2
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
20.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
3
15.4M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RCUS News & Events
Events Timeline
2025-07-10 (ET)
2025-07-10
08:34:20
Arcus Biosciences quemliclustat granted orphan drug designation by FDA

2025-06-30 (ET)
2025-06-30
21:19:46
Arcus Biosciences treatment of pancreatic cancer granted orphan designation


2025-06-01 (ET)
2025-06-01
16:11:54
Arcus Biosciences presented data for casdatifan plus cabozantinib

Sign Up For More Events
Sign Up For More Events
News
5.0
07-24NewsfilterArcus Biosciences Announces New Employment Inducement Grants
9.0
07-10NASDAQ.COMArcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer
9.0
07-10SeekingAlphaArcus says Gilead-partnered cancer drug won FDA orphan status
Sign Up For More News
People Also Watch

LEU
Centrus Energy Corp
241.000
USD
-0.55%

ALEX
Alexander & Baldwin Inc (Hawaii)
18.410
USD
+1.99%

DCBO
Docebo Inc
31.430
USD
+0.16%

ATUS
Altice USA Inc
2.680
USD
-9.15%

AGL
agilon health inc
2.060
USD
-0.48%

HCI
Hci Group Inc
138.300
USD
-0.50%

NSSC
NAPCO Security Technologies Inc
30.420
USD
+2.42%

SMWB
Similarweb Ltd
8.650
USD
-1.14%

INMD
Inmode Ltd
14.720
USD
+1.31%

AIV
Apartment Investment and Management Co
8.660
USD
-0.12%
FAQ

What is Arcus Biosciences Inc (RCUS) stock price today?
The current price of RCUS is 10.23 USD — it has increased 3.65 % in the last trading day.

What is Arcus Biosciences Inc (RCUS)'s business?

What is the price predicton of RCUS Stock?

What is Arcus Biosciences Inc (RCUS)'s revenue for the last quarter?

What is Arcus Biosciences Inc (RCUS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arcus Biosciences Inc (RCUS)'s fundamentals?

How many employees does Arcus Biosciences Inc (RCUS). have?
